<SEC-DOCUMENT>0001213900-26-047735.txt : 20260427
<SEC-HEADER>0001213900-26-047735.hdr.sgml : 20260427
<ACCEPTANCE-DATETIME>20260427074440
ACCESSION NUMBER:		0001213900-26-047735
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20260427
DATE AS OF CHANGE:		20260427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allarity Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001860657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-293420
		FILM NUMBER:		26896568

	BUSINESS ADDRESS:	
		STREET 1:		24 SCHOOL ST., 2ND FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02108
		BUSINESS PHONE:		401-426-4664

	MAIL ADDRESS:	
		STREET 1:		24 SCHOOL ST., 2ND FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02108
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0287713-424b3_allarity.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-293420</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ea028771301_img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>255,103 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered by the Selling Stockholder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus relates to the resale, from time to time, by the selling
stockholder identified herein, of up to 255,103 shares of common stock, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;),
of Allarity Therapeutics, Inc. (the &ldquo;Company&rdquo;) (the &ldquo;Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Common Shares were issued to the selling stockholder in a private
placement completed on December 23, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder may, from time to time,
sell, transfer or otherwise dispose of all or a portion of the securities described in this prospectus through public or private transactions,
at prevailing market prices or at negotiated prices, and by various methods. See &ldquo;<I>Plan of Distribution</I>&rdquo; beginning
on page 10 of this prospectus for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are not offering any shares of Common Stock under this prospectus
and will not receive any proceeds from the sale of the shares by the selling stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Common Stock is listed on The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;)
under the symbol &ldquo;ALLR.&rdquo; On April 23, 2026, the last reported sale price of our Common Stock on Nasdaq was $1.40 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus provides a general description
of the securities being offered. You should carefully read this prospectus, together with the accompanying registration statement and
the documents incorporated by reference, before making any investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are an &ldquo;emerging growth company&rdquo;
as defined in Section 2(a) of the Securities Act and are subject to reduced public company reporting requirements. This prospectus complies
with the requirements that apply to an issuer that is an emerging growth company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves significant
risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any accompanying prospectus supplement,
as well as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange
Commission. See &ldquo;<I>Risk Factors</I>&rdquo; on page&nbsp;5&nbsp;of this prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NEITHER THE SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS.
ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is April 27, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%"><A HREF="#k_001"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; width: 9%; vertical-align: bottom"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_002"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">iii</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_003"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_004"><FONT STYLE="font-size: 10pt">THE OFFERING</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_005"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_006"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_007"><FONT STYLE="font-size: 10pt">MARKET FOR COMMON STOCK AND DIVIDEND POLICY</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_008"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_009"><FONT STYLE="font-size: 10pt">SELLING STOCKHOLDER</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_010"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_011"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_012"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#k_013"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#k_014"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&ensp;</FONT></TD>
    <TD STYLE="text-align: center; white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_001"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents we have
filed with the SEC that are incorporated by reference herein and therein contain forward-looking statements within the meaning of
Section 27A of the Securities Act&nbsp;and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). In addition, from time to time we or our representatives have made or will make forward-looking statements in various
other filings that we make with the SEC or in other documents, including press releases or other similar announcements.
Forward-looking statements concern our current plans, intentions, beliefs, expectations and statements of future economic
performance. Statements containing terms such as &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;believe,&rdquo; &ldquo;do not
believe,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate&rdquo; and
other phrases of similar meaning are considered to be forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward-looking statements are based on our assumptions
and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those reflected
in or implied by these forward-looking statements. Factors that might cause actual results to differ include, among others, those set
forth under &ldquo;Risk Factors&rdquo; in this prospectus and those discussed in &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operation</I>&rdquo; in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports
on Form 10-Q and in our future periodic reports filed with the SEC, all of which are incorporated by reference herein. Readers are cautioned
not to place undue reliance on any forward-looking statements contained in this prospectus or the documents we have filed with the SEC
that are incorporated by reference herein and therein, which reflect management&rsquo;s views and opinions only as of their respective
dates. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other
factors affecting such forward-looking statements, except to the extent required by applicable securities laws. You are advised, however,
to consult any additional disclosures we have made or will make in the filings we make with the SEC, including reports on Forms 10-K,
10-Q and 8-K. All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in
their entirety by the cautionary statements contained in this prospectus or any related issuer free writing prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="k_002"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration statement
that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration process. By using
a shelf registration statement, the selling stockholder may sell shares of our Common Stock from time to time and in one or more offerings
as described in this prospectus and may provide a prospectus supplement to this prospectus that contains specific information about the
shares of our Common Stock being offered and sold and the specific terms of that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free
writing prospectus may also add, update or change information contained in this prospectus with respect to that offering. If there is
any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you
should rely on the prospectus supplement or free writing prospectus, as applicable. Before purchasing any shares of our Common Stock,
you should carefully read both this prospectus and any applicable prospectus supplement and free writing prospectuses, together with
the additional information described under the heading &ldquo;<A HREF="#k_014"><I>Where You Can Find Additional Information</I></A>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Neither we, the selling stockholder nor any underwriter
has authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus,
any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you.
Neither we, the selling stockholder nor any underwriter takes responsibility for, and can provide no assurances as to the reliability
of, any other information that others may give you. Neither we nor the selling stockholder will make an offer to sell the shares of our
Common Stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus
and any applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information
appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus and that any information
incorporated by reference is accurate only as of the date of the document incorporated by reference, unless indicated otherwise. Our business,
financial condition, results of operations and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus
were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among
the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations,
warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should
not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus includes summaries of certain
provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information.
All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have
been filed, will be filed or are incorporated by reference as exhibits to the registration statement of which this prospectus is a part,
and you may obtain copies of those documents as described under the heading &ldquo;<A HREF="#k_014"><I>Where You Can Find Additional Information</I></A>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The terms &ldquo;Allarity,&rdquo; the &ldquo;Company,&rdquo;
&ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;we,&rdquo; as used in this prospectus, refer to Allarity Therapeutics, Inc., a Delaware
corporation, and its subsidiaries unless we state otherwise or the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B><A NAME="k_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary description about us and our
business highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus.
It does not contain all the information you should consider before investing in our securities. You should carefully read the entire
prospectus, any applicable prospectus supplement, and any related free writing prospectus, including the risks of investing in our
securities discussed under the heading &ldquo;<A HREF="#k_005">Risk Factors</A>&rdquo; contained in this prospectus, any applicable
prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are
incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this
prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus forms a
part.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage, precision medicine pharmaceutical
company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation
of our novel Drug Response Predictor (DRP&reg;) platform. The DRP&reg; technology is designed to define the gene expression signatures
in cancer cells that predict the cancer cell&rsquo;s sensitivity to a specific cancer therapeutic. Once defined, the DRP&reg; gene expression
signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity,
and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic.
We have developed and published DRP&reg; signatures for dozens of anti-cancer therapeutics. Ideally, by using DRP to identify the
patients most likely to benefit clinically from a given therapeutic, clinical development of that therapeutic can be focused on a smaller,
more responsive patient population, which would allow for smaller, cheaper and quicker trials while also enhancing the probability of
clinical and regulatory success for that therapeutic. Historically, we have generated DRP signatures for numerous anti-cancer therapeutics
and had in-licensed numerous assets for DRP-guided development, including Liposomal CisPlatin (LiPlaCis), Irofulven and dovitinib as well
as the novel PARP/tankyrase inhibitor, stenoparib.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are now singularly focused on the development of stenoparib and
the parallel development of the stenoparib DRP&reg; as a companion diagnostic. All other assets including dovitinib, Irofulven and LiPlaCis,
were terminated and are no longer part of our portfolio. Stenoparib was in-licensed with exclusive world-wide rights from the Japanese
Pharmaceutical company, Eisai Pharmaceuticals. Stenoparib is a novel, dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) as well as
tankyrases, enzymes critically important in the WNT cancer cell survival pathway. Stenoparib is currently being explored in a phase 2
clinical trial in patients with advanced, recurrent ovarian cancer who have been pre-selected for enrollment using the stenoparib-DRP&reg;.
Emerging clinical data from this ongoing trial in heavily pre-treated, advanced ovarian cancer patients show promising clinical benefit
including a patient with a complete, confirmed response (i.e., absence of active disease by RECISTv1.1 criteria) as well as a patient
with primary platinum refractory disease who stayed on therapy more than 10 months and two additional patients who stayed on therapy with stable disease more than 27 months. These compelling data in heavily pre-treated
ovarian cancer patients have now prompted us to design a new clinical protocol, guided by key gynecologic oncology experts, to deepen
and enrich the understanding of the clinical benefit from stenoparib treatment while also advancing the stenoparib-DRP&reg; as a companion
diagnostic used to select patients for stenoparib treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>PIPE Financing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 22, 2025, we entered into a Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with the selling stockholder named in this prospectus pursuant to which the
Company agreed to sell, in a private placement (the &ldquo;Private Placement&rdquo;), 760,916 shares of our common stock, par value $0.0001
per share (the &ldquo;Common Stock&rdquo;), at a purchase price of $1.60 per share, and 801,584 pre-funded warrants (the &ldquo;Pre-Funded
Warrants&rdquo;) at a purchase price of $1.5999 per Pre-Funded Warrant. Each Pre-Funded Warrant is immediately exercisable to purchase
one share of Common Stock for $0.0001 per share. The closing of the Private Placement occurred on September 23, 2025, resulting in gross
proceeds to the Company of approximately $2.5 million, before deducting fees and expenses. We intend to use the funds from the Offering
for our working capital needs and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></DIV>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Purchase Agreement, the selling stockholder has the right,
for a period of ninety (90) calendar days following the initial closing, to purchase additional shares of Common Stock and/or Pre-Funded
Warrants for aggregate gross proceeds of up to $7.5 million (the &ldquo;Additional Closing&rdquo;), with the purchase price per share
to be equal to the then-current &ldquo;Minimum Price,&rdquo; as defined in Nasdaq Stock Market Rule 5635(d), and the purchase price per
Pre-Funded Warrant equal to such Minimum Price less the $0.0001 exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Additional Closing of
the Private Placement occurred on December 23, 2025, subject to customary closing conditions. At the Additional Closing, the Company issued
and sold 255,103 shares (the &ldquo;Additional Shares&rdquo;) of the Company&rsquo;s Common Stock, for $0.98 per Share, representing the
Minimum Price under Nasdaq Rule 5635(d), for gross proceeds to the Company of approximately $250,000, before deducting fees and expenses.
We intend to use the net proceeds from the sale of the Additional Shares for general corporate purposes and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><U>ELOC Purchase Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 28, 2026, we entered
into a Common Stock Purchase Agreement (the &ldquo;ELOC Purchase Agreement&rdquo;) with Tumim Stone Capital LLC (the &ldquo;Investor&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the ELOC Purchase Agreement,
we may, at our option, sell shares of our common stock to the Investor from time to time. The maximum amount we may sell is the lesser
of (i) $6.0 million of newly issued shares of our common stock and (ii) the applicable exchange cap set forth in the ELOC Purchase Agreement.
We are not required to sell any shares under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were founded in Denmark in 2004 by our chief
scientific officer, Steen Knudsen, Ph.D., and our Chief Executive Officer, Thomas H. Jensen, both of whom were formerly academic researchers
at the Technical University of Denmark working to advance novel bioinformatic and diagnostic approaches to improving cancer patient response
to therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were incorporated in Delaware in 2021. On May
20, 2021, we entered a Plan of Reorganization and Asset Purchase Agreement (the &ldquo;Recapitalization Share Exchange&rdquo;), between
us, Allarity Acquisition Subsidiary, our wholly owned Delaware subsidiary (&ldquo;Acquisition Sub&rdquo;), and Allarity Therapeutics A/S,
an Aktieselskab organized under the laws of Denmark. Pursuant to the terms of the Recapitalization Share Exchange, our Acquisition Sub
acquired substantially all of the assets and liabilities of Allarity Therapeutics A/S in exchange for shares of our common stock on December
20, 2021, and our common stock began trading on the Nasdaq Global Market on that same day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located at
123 E Tarpon Ave, Tarpon Springs, FL 34689. Our telephone number is (401) 426-4664, and our email address is info@allarity.com. Our corporate
website address is www.allarity.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P></DIV>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>Implications of Being an Emerging Growth
Company and a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We qualify as an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). As an emerging growth company, we may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">exemptions from the requirements of holding a nonbinding advisory
vote on executive compensation and stockholder approval of any golden parachute payments not previously approved; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">an extended transition period for complying with new or revised
accounting standards.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may take advantage of these provisions until
we no longer qualify as an emerging growth company. We will cease to qualify as an emerging growth company on the date that is the earliest
of: (i) December 31, 2026, (ii) the last day of the fiscal year in which we have more than $1.235 billion in total annual gross revenues,
(iii) the date on which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the rules of the SEC, which means the market
value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, or (iv) the date on
which we have issued more than $1.0 billion&nbsp;of non-convertible debt over the prior three-year period. We may choose to take
advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in
this prospectus. Accordingly, the information contained herein may be different than you might obtain from other public companies in which
you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, under the JOBS Act, emerging
growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.
We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain
of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will
not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging
growth companies, which may make comparison of our financials to those of other public companies more difficult. As a result of these
elections, the information that we provide in this prospectus may be different than the information you may receive from other public
companies in which you hold equity interests. In addition, it is possible that some investors will find our common stock less attractive
as a result of these elections, which may result in a less active trading market for our common stock and higher volatility in our share
price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also a &ldquo;smaller reporting company,&rdquo;
meaning that the market value of our shares held&nbsp;by non-affiliates is&nbsp;less than $700 million and our annual revenue was less
than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the
market value of our shares held&nbsp;by non-affiliates is&nbsp;less than $250 million or (ii) our annual revenue was less than $100 million
during the most recently completed fiscal year and the market value of our shares held&nbsp;by non-affiliates is&nbsp;less than $700 million.
If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from
certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may
choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on&nbsp;Form 10-K and,&nbsp;similar
to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_004"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 20%"><B>Shares of Common Stock Offered</B></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top; width: 78%">Up to 255,103 shares of Common Stock.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Shares of Common Stock offered by us</B></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">None.</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><B>Common Stock outstanding before this offering</B></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,080,980 shares of Common Stock.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Common Stock to be outstanding after this offering<SUP>(1)</SUP></B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">16,080,980 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Common Stock</FONT>.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Use of Proceeds</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">We will not receive any proceeds from the sale of Shares by the selling stockholder.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Plan of distribution</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">The selling stockholder may sell or otherwise dispose of the Shares from time to
time in transactions on Nasdaq, in negotiated transactions, or otherwise, at market prices prevailing at the time of sale or at negotiated
prices. See &ldquo;<A HREF="#k_010"><I>Plan of Distribution</I></A>&rdquo; for additional information.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Nasdaq Capital Market symbol</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&ldquo;ALLR.&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Risk factors</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Investing in our Common Stock involves significant risks. See &ldquo;<A HREF="#k_005"><I>Risk Factors</I></A>&rdquo; and other information included or incorporated by reference in this prospectus.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify">Excludes (i) the issuance and sale of up to $6.0 million of newly issued
shares of our common stock that we may sell to Tumim Stone Capital, LLC and (ii) shares of Common Stock issuable upon the exercise of
outstanding stock options, warrants or other derivative securities.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</DIV>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="k_005"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Investing
in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks
described in this prospectus and in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC,
each of which are incorporated by reference in this prospectus, and all of the other information in this prospectus, including our
financial statements and related notes incorporated by reference herein. If any of these risks is realized, our business, financial
condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our
common stock could decline and you could lose part or all of your investment. Additional risks and uncertainties that are not yet
identified or that we currently believe to be immaterial may also materially harm our business, financial condition, results of
operations and prospects and could result in a complete loss of your investment. This prospectus and the documents incorporated
herein by reference also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ
materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned
elsewhere in this prospectus. For additional information, see &ldquo;<A HREF="#k_014">Where You Can Find Additional Information</A>.&rdquo; Please also read carefully the above section &ldquo;Cautionary Note Regarding Forward-Looking
Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Risks Related to This
Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of substantial amounts of our Common Stock, including by
the selling stockholder, could cause our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The market price of our Common Stock could be adversely
affected by sales of substantial amounts of our Common Stock in the public market, or the perception that such sales may occur. This includes
sales by the selling stockholder pursuant to this prospectus. In addition, future issuances of our Common Stock by us, whether in connection
with capital raising transactions, acquisitions, or otherwise, could dilute existing stockholders and further depress the market price
of our Common Stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience future dilution as a result of future equity
offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to raise additional capital, we may in
the future offer additional shares of Common Stock or other securities convertible into or exchangeable for our shares of Common Stock
that could result in further dilution to our current stockholders or result in downward pressure on the price of our Common Stock. We
may sell our shares of Common Stock or other securities in any offering at prices that are higher or lower than the prices paid by the
selling stockholder, and the investors purchasing shares or other securities in the future could have rights superior to existing stockholders.
Moreover, to the extent that we issue options or warrants to purchase, or securities convertible into or exchangeable for, our shares
of Common Stock in the future and those options, warrants or other securities are exercised, converted or exchanged, stockholders may
experience further dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will not receive any of the proceeds from the
sale of the Shares in this offering. The selling stockholder will receive all of the proceeds from the sale of the Shares hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will bear
the&nbsp;out-of-pocket&nbsp;costs, expenses and fees, including legal fees, incurred in connection with the registration of the
Shares to be sold by the selling stockholder pursuant to this prospectus. Other than registration expenses, the selling stockholder
will bear its own broker or similar commissions payable with respect to sales of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_007"></A>MARKET FOR COMMON STOCK AND DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Common Stock is listed on the Nasdaq Capital
Market under the symbol &ldquo;ALLR.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not declared or paid any dividends on our
Common Stock to date. We currently intend to retain all available funds and future earnings, if any, to support the development and growth
of our business, and therefore do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends
will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contractual restrictions, business prospects, and other factors our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_008"></A>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The descriptions of the
Securities contained in this prospectus, together with any applicable prospectus supplements, summarize the material terms and provisions
of the Securities being offered pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The following description
of our Common Stock is a summary. This summary is qualified in its entirety by reference to the Delaware General Corporation Law (&ldquo;DGCL&rdquo;)
and to the complete text of our Certificate of Incorporation, as amended to date, and Amended and Restated Bylaws, as amended to date.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our authorized capital
stock consists of shares made up of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">250,000,000 shares of Common
Stock, par value $0.0001 per share; and</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">500,000 shares of undesignated
preferred stock, par value $0.0001 per share, the rights and preferences of which may be established from time to time by our Board of
Directors.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of our Common Stock are entitled to one
vote for each share held of record on all matters submitted to a vote of stockholders, including the election or removal of directors,
except for any directors who are elected exclusively by the holders of a class of our preferred stock that entitles that class of stock
to elect one or more directors. The holders of our common stock do not have cumulative voting rights in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon our liquidation, dissolution or winding up
and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences,
if any, the holders of our common stock (and the holders of any preferred stock that may then be outstanding, to the extent required
by our Certificate of Incorporation, including any certificate of designation with respect to any series of preferred stock) will be
entitled to receive pro rata our remaining assets available for distribution, unless holders of a majority of the outstanding shares
of common stock approve a different treatment of the shares. Holders of our common stock do not have preemptive, subscription, redemption
or conversion rights. Our common stock will not be subject to further calls or assessment by us. There will be no redemption or sinking
fund provisions applicable to our common stock. All shares of our common stock that will be outstanding at the effective time will be
fully paid and non-assessable. The rights, powers, preferences and privileges of holders of our common stock will be subject to those
of the holders of our Series A Preferred Stock and any other shares of preferred stock we may authorize and issue in the future.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The transfer agent
and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&rsquo;s address is 150 Royall Street,
Canton, MA 02021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_009"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are registering the resale of the Shares <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
satisfy our contractual obligations under a registration rights agreement with the selling stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Beneficial ownership is determined in accordance
with the rules of the SEC and generally includes voting or investment power with respect to our Common Stock. A person is deemed to &ldquo;beneficially
own&rdquo; shares if such person has or shares voting or disposition rights, or the right to acquire such rights within 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table below sets forth information regarding the selling stockholder
and its beneficial ownership of our Common Stock. The information in the table has been furnished by the selling stockholder or derived
from its public filings with the SEC. The second column lists the number of shares of Common Stock beneficially owned by the selling stockholder
as of April 24, 2026. The actual number of shares beneficially owned, as determined in accordance with SEC rules, may be less than the
amount shown. The third, fourth and fifth columns assume the sale of all of the Shares offered by the selling stockholder pursuant to
this prospectus. The percentage of shares beneficially owned after the offering in the fourth column is based on 15,818,980 shares of
Common Stock outstanding as of April 24, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder may sell all, some or
none of the Shares offered by this prospectus. See &ldquo;<A HREF="#k_010"><I>Plan of Distribution</I></A>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder has represented to us that
it is not an affiliate of the Company and has not held any position, office, or other material relationship with us within the past three
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Selling Stockholder</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Beneficially Owned Before Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Shares Being Offered</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Beneficially Owned After Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percentage of Outstanding Common Stock After Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%; padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">3i, LP<SUP>(2)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">1,</FONT>407,865</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">255,103</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">801,584</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><SUP>(4)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">4.98</TD>
    <TD STYLE="width: 1%">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify">Assumes <FONT STYLE="font-size: 10pt">the </FONT>sale of
all <FONT STYLE="font-size: 10pt">shares of Common Stock</FONT> offered pursuant to this prospectus<FONT STYLE="font-size: 10pt">.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="text-align: justify">3i Management LLC is the general partner of 3i, LP, and Maier
Joshua Tarlow is the manager of 3i Management LLC. As such, Mr. Tarlow exercises sole voting and investment discretion over securities
beneficially owned directly or indirectly by 3i, LP and 3i Management LLC. Mr. Tarlow disclaims beneficial ownership of the securities
beneficially owned directly by 3i, LP and indirectly by 3i Management LLC. The business address of each of the aforementioned parties
is 2 Wooster Street, 2nd Floor, New York, NY 10013. We have been advised that none of Mr. Tarlow, 3i Management LLC, or 3i, LP is a member
of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a
FINRA member or independent broker-dealer.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="text-align: justify">Includes: (i) 606,281 shares of Common Stock and (ii) 801,584
shares of Common Stock underlying pre-funded warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(4)</SUP></TD><TD STYLE="text-align: justify">Includes 801,584 shares of Common Stock underlying pre-funded
warrants.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="k_010"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder, or its pledgees, assignees,
transferees, distributees, beneficiaries, or other successors-in-interest, may, from time to time, sell, transfer, or otherwise dispose
of any or all of the Shares covered by this prospectus on the Nasdaq Capital Market, on any other securities exchange or quotation service
on which our Common Stock may be listed or quoted, in the over-the-counter market, or in private transactions. These sales may be made
at prevailing market prices, at fixed prices, at prices related to prevailing market prices, or at privately negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder may use one or more of
the following methods when disposing of the Shares:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">ordinary brokerage transactions, including transactions in
which a broker-dealer solicits purchasers;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">block trades in which a broker-dealer attempts to sell the
Shares as agent, but may position and resell a portion as principal to facilitate the transaction;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">purchases by a broker-dealer as principal and resale by the
broker-dealer for its own account;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">exchange distributions in accordance with the rules of the
applicable exchange;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">privately negotiated transactions;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">through agreements with broker-dealers to sell a specified
number of Shares at a stipulated price per share;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">through the writing or settlement of options or other hedging
transactions, whether through an options exchange or otherwise;</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">a combination of any such methods; or</TD>
</TR></TABLE>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">any other method permitted under applicable law.</TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder may also sell Shares under
Rule 144 or any other available exemption from registration under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Broker-dealers engaged by the selling stockholder
may arrange for other broker-dealers to participate in resales. Broker-dealers may receive commissions or discounts from the selling stockholder
(or, if acting as agent for the purchaser, from the purchaser) in amounts to be negotiated, but not in excess of customary brokerage commissions
in compliance with FINRA Rule 2121. In the case of principal transactions, a markup or markdown may be charged in compliance with FINRA
Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with sales of the Shares, the selling
stockholder may enter into hedging transactions with broker-dealers or other financial institutions. Those broker-dealers or financial
institutions may in turn engage in short sales of the Shares in the course of hedging the positions they assume. The selling stockholder
may also sell Shares short and deliver the Shares to close out such short positions, or loan or pledge Shares to broker-dealers that may
in turn sell such Shares. In addition, the selling stockholder may enter into options or other derivative transactions with broker-dealers
or other financial institutions, which may involve the delivery of Shares offered by this prospectus to such broker-dealer or financial
institution, who may then resell or otherwise transfer such Shares pursuant to this prospectus (as supplemented or amended to reflect
such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The selling stockholder and any broker-dealers
or agents participating in the sale of the Shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the Shares purchased by
them may be deemed to be underwriting discounts or commissions under the Securities Act. The selling stockholder has informed us that
it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the Shares.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are required to pay certain fees and expenses
incurred by us incident to the registration of the Shares. We have agreed to indemnify the selling stockholder against certain liabilities,
including liabilities under the Securities Act. The selling stockholder will bear all underwriting discounts, selling commissions, and
any similar expenses incurred in connection with the sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are obligated to maintain the effectiveness
of the registration statement of which this prospectus forms a part until all of the Shares and Pre-Funded Warrant Shares registered hereunder
(i) have been sold pursuant to this prospectus or Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant
to Rule 144 and without the requirement for us to be in compliance with the current public information requirement under Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The resale of the Shares will be made only through
registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale
of the Shares may not be made unless they have been registered or qualified for sale in the applicable state or an exemption from registration
or qualification is available and complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under applicable rules and regulations of the Exchange Act, any person
engaged in the distribution of the Shares may not simultaneously engage in market-making activities with respect to the Common Stock for
the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling
stockholder will be subject to Regulation M, which may limit the timing of purchases and sales of the Shares by the selling stockholder
or any other person. We will make copies of this prospectus available to the selling stockholder and have informed the selling stockholder
of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of sale (including by compliance with Rule
172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities being offered hereby
will be passed upon for us by Venable LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_012"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
Allarity Therapeutics, Inc. as of December 31, 2025 and 2024, and for each of the two years in the period ended December 31, 2024,
are incorporated in this prospectus by reference from Allarity Therapeutics, Inc.&rsquo;s <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001860657/000143774926010310/allr20251231_10k.htm">Annual
Report on Form 10-K</A> for the year ended December 31, 2025, have been audited by Wolf &amp; Company, P.C., an independent
registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such consolidated financial
statements are incorporated by reference in reliance upon the report of such firm given their authority as experts in accounting and
auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_013"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate by reference&rdquo;
information from other documents that we file with it, which means that we can disclose important information to you by referring you
to those publicly available documents. The information incorporated by reference is considered to be part of this prospectus. Information
in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus, while
information that we file later with the SEC will automatically update and supersede the information in this prospectus. This means that
you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in
any document previously incorporated by reference have been modified or superseded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We incorporate by reference into this prospectus
the information or documents listed below that we have filed under the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001860657/000143774926010310/allr20251231_10k.htm">Form
10-K</A> for the year ended December 31, 2025 filed with the SEC on March 30, 2025;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Current Reports on Form 8-K filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1860657/000121390026009157/ea0274173-8k_allarity.htm">January
29, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001860657/000121390026011826/ea0275506-8k_allarity.htm">February
4, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1860657/000121390026018161/ea0277546-8k_allarity.htm">February
19, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1860657/000121390026024339/ea0279478-8k_allarity.htm">March 6,
2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1860657/000121390026024952/ea0280539-8k_allarity.htm">March 9, 2026</A>,
and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1860657/000121390026046411/ea0287156-8k_allarity.htm">April 22, 2026</A>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1860657/000143774925013914/allr20250422_def14a.htm">Schedule
14A</A>, filed with the SEC on April 30, 2025; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">The description of our common stock contained <A HREF="https://www.sec.gov/Archives/edgar/data/1860657/000121390023019295/f10k2022ex4vi_allarity.htm">Exhibit
4(vi)</A> to our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1860657/000121390023019295/f10k2022_allaritytherap.htm">Form
10-K</A> filed with the SEC on March 13, 2023, including any amendments thereto or reports filed for the purpose of updating such description.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, all <FONT STYLE="font-size: 10pt">documents
</FONT>subsequently <FONT STYLE="font-size: 10pt">filed by us </FONT>(excluding any information furnished rather than filed) <FONT STYLE="font-size: 10pt">pursuant
to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act</FONT>, <FONT STYLE="font-size: 10pt">prior to the termination of the offering
shall be deemed to be incorporated by reference into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any statement contained in this prospectus or in
<FONT STYLE="font-size: 10pt">any document </FONT>incorporated or deemed to be incorporated by reference into this prospectus will be
<FONT STYLE="font-size: 10pt">deemed </FONT>modified or superseded for the purposes of this prospectus to the extent that a statement
contained in this prospectus or any subsequently <FONT STYLE="font-size: 10pt">filed </FONT>document which also is, or <FONT STYLE="font-size: 10pt">is
deemed to be</FONT>, <FONT STYLE="font-size: 10pt">incorporated by reference into this prospectus</FONT> modifies or supersedes that statement.
Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus<FONT STYLE="font-size: 10pt">.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You may obtain any of the documents incorporated
by reference in this prospectus from the SEC through the SEC&rsquo;s website at the address provided above. You may also request and we
will provide, free of charge, a copy of any document incorporated by reference in this prospectus (excluding exhibits to such document
unless an exhibit is specifically incorporated by reference in the document) by writing or calling us at the following address and telephone
number:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Allarity Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">123 E Tarpon Ave</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tarpon Springs, FL 34689</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (401) 426-4664</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn.: Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information contained
in, or incorporated by reference into, this prospectus, in any accompanying prospectus supplement, or in any free writing prospectus filed
by us with the SEC. We have not authorized anyone to provide you with different or additional information. We are not offering to sell
or soliciting any offer to buy any securities in any jurisdiction where the offer or sale is not permitted. You should not assume that
the information in this prospectus or in any document incorporated by reference is accurate as of any date other than the date on the
front cover of the applicable document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="k_014"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed with the SEC a registration statement
on Form S-3 under the Securities Act with respect to the common stock offered by this prospectus. This prospectus, which constitutes a
part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained
in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to
us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement.
Statements contained in this prospectus concerning the contents of any contract or any other documents are not necessarily complete. If
a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that
has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects
by the filed exhibit. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information
regarding issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are subject to the information reporting requirements
of the Exchange Act, and we file reports, proxy statements and other information with the SEC. These reports, proxy statements and other
information will be available at website of the SEC referred to above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also maintain a website at www.allarity.com.
Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address
in this prospectus is only as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Upon request, we will provide, without charge, to each person, including
any beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus
but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by
reference as an exhibit in this prospectus, at no cost by writing us at the Company address provided above in section titled &ldquo;<A HREF="#k_013"><I>Incorporation of Certain Information By Reference</I></A><I>.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>255,103 Shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered by the Selling Stockholder</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><IMG SRC="ea028771301_img2.jpg" ALT="" STYLE="width: 394px; height: 142px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROSPECTUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>April 27, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not authorized any dealer, salesperson
or other person to give any information or represent anything not contained in this prospectus. You must not rely on any unauthorized
information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not offer
to sell any securities in any jurisdiction where it is unlawful. Neither the delivery of this prospectus, nor any sale made hereunder,
shall create any implication that the information in this prospectus is correct after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea028771301_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028771301_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "% 8H# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW"HKA/"'C72/&WA'1O&^AWMM<Z-KVD_VU97?8Z;C<6^@ZDGOU[&NS_>_YW4
M6**K_O?\[JL4 %%%% !1110 4444 %%%% !1110 4444 5ZK7G^J'T/\S6C2
M'H<>AH Y^^_UA@SS]D..W'/N>0,^QQU%?B?^U!X6G\._%ZXU#C[!K]V;X@>O
M0C\_3COZX_<7<IAY'J.?3!'?KT'3Z^N/C']J3X1CQGX?N-4T^'_B;VO-F>N?
M7&/4Y/!/7G.*_DOZ3'AGB.*^'*N,P2<I04Y.*C>S4)RNTD]7;>U_-'Z?X6\2
M87(>(Z;Q;]V=HN[MK*44NJ2W:WT^=S\B9H<VUQ/!Q_IGY8(_/J..>_I5>J]Y
MIL\-U<6,^;;4+6\]1ST^GJ3U^F*L?ZK_ #G.?R]/;I^?^#W%&5/)N),VP6,3
MC*,ZD4W%IWC*<?=T3W70_P!%<)C(X[!99+!N,U*,9:-2LG%2UM?OU^\*T;.'
MSM>\/^GVS\1G_(Z'\ZSIO(FM+B"?_GSZ<_\ UNGO_P#6KL/A[9_VE\2_"_\
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MGG7M_<:HUQ;W%N;5;,$>JL&Y.#P<<CC()!SG%=E2 **** "BBL;4L^=!Y/\
MK\G_ +YXQ[YZ?I[T 6)Y;>+KS^9.WJ<=1V!Z9[5S^HRV-V)[8#[3QT' S^F?
M\X/-9YO8 +B>>].F_9/^/P7>/[-^HR0.F>X[>M?#'Q^_X*-?LH?LZV%S!XJ^
M(&B:WJ%KT\/:3>'^U/7Z?_6_7BS7 +,<%4P*AS^UA.GR_$FYQE!75FOM:^HX
MU<+@9+&XN3C.-I+5III\R^TGNN_J>:?M,_ -M/N;GQQX>M\7(/\ IEH!P1R
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M7Q2_Q2_-G0?YJ'_!;WX;S_#']M?P_P"%=5US4O&^H75GX7_XFMU>_P#'@/\
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M5B\3C%)8F5XZI6E?37HGV*\T,'F^?Y'Z\=L_ET_EP*L3PP>5]GN(/M%O<_\
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MR_%8)<UHVM%)[)Z:7Z??<_H?PEX2Q7$6,C'%^\N:/N[Z.2TM9[W_ !9_)_\
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M!;5=<  W$#YB  HSD@<9KU'_ (+M?LEP_M.?L;ZSXCTNR!\<?"^T_P"$GL0
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MN?7\_P#]7MH:=,=-NK><9^T6OZ>P.,^GZT>=_I?^U_GVQTJ#SH+R:W\CM_\
M6Q]!W/XC(SFO\=^$:_$%7Q#PV#RI/)^7%8>,[7BYQCB*/-MROWE&6^US^_\
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MASC@>PR#QFO5PV987%W2DNUKWU3>UGIJ]4]-A?5M_=_!:_A^9Y=\)O@OX/\
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MQQ[]Z^6S#,Y2UC>]]-_Q_)KY,^ORW+?JMM.VEK^?7\^A!.!_H\, _P!'NO\
MC[]\CZ<9[]>*X?QMX/TOQ)H5_H>JV/VFVNK/%I],' &.^<'N,5Z!#%,.3T/3
MKD<_XCN, =>HQ/+$2/(.1!@$C!&,XX/'/.><\YZ<5\'Q#D<.+<GS++L;%-5(
M5(PC-)Q;<)15E*+C>TELCV\'BI8+&QG'F5IQ:E&Z:Y9)O5-/9=S\$OC-\,=5
M^&/B3[%Y%S<^'[J\^V_VKP>_\\\'Z#IFN.\$Z#!KWC?P?H=CFYT^ZO"/M>?S
M[XST_P *_:[XA?"S1/&MI?Z'JM@+G3S:#[)R< $'WY(;'MC(XQFOCGX8_LWZ
MKX)^(UO^_MM2T>UO/MME_H?Z\9/Y>E?YVXWZ++R#C^&>1A[CQ$:JY8NUO;QG
MK:-MMO(_IG+_ !8]APU++Y3O-TG!N3;E[U-Q3NVWUU71W1^BGA"R%EX>TZRZ
M_9[,+GJ0>>>QQ[_7K791_P"IA_W?Y&J5G"88L#U_Q _0]^Y].DTL1,1\D8Y]
M_P"I]<>U?Z-<+9:L#EU&'PN-*C%75MJ<(]4M-.WH?S;C<2JN-J3_ .?DZD[Z
MO6<Y2;_\F^>ACZA907<%\)X;=N -QZ\<98$?ET[]\U\[_"#3;'^WO'$WD6P^
MRZQP<#C(Z=?0?H>G6OIF\A\^UN( ,=L?CSQZ?S_2O-O!/P^G\*ZGK-]/??:C
MJEX;WCKGW'\SQ_4Z8G+U+,E)7M*/R]Z.C=M+ZFM#$I)KI9V_+\?+OZ,\W^/L
MLX\+V$\$!YUC2L]/^@R!^?&>_7I5G6-2\8_\*^U&>>QM?LXT;CZ?EG\/;Z5Z
M-X]\"S^+]+T^QAOH+;[+>"]_TH%B?;"@^F.GN,ULZEX7FO/#ESH?GC%S9?8R
M3QZ\Y./KS7R>(X>D\9S)R^*^DG;27D_Z17UGL]%Y[?B<-\&<WG@33IYN9\'/
MY<?B#D>O7M7B/P]U+Q5/KWC">#0].N;?^V?L6;O(_P"8UWQWZGW R.<&OI_P
M?X5F\*Z#;Z3Y]M<_9>?3'X_CTX[X]:\PL_ACXCTW5-8OK'Q';6UOJEY]M^R?
M8\\9QSCD^OOW KMS##2PN*RS1R5ES6YFNGQ6O^)NL1J_>O=K332R7G\SUBSA
MA\JW@\C[-<?9.MKGC((XZXY&<=.OTKYW\8:Q/9?$N?\ LK0[;4]0M;(=<<_C
MG\?K7O'A71_$=G%<?VYJEMJ5QQ]DO!:$'/KUSQ[$]/456A\">3XMN/%0O;?-
MR!QCDG'09X)&!QGGVQD^CF6%>)P>EU:+T2=];^G]6%]9LWKT[M_KY[79X1X5
MAG\5>-KC6[V"VT0Z7_Q^6EIGG\/KWXQ77_%_Q5!X5\)7%Q?9N;?5;O\ XE L
M\_VCGCD!L>IY].I)P:ZZ;X9SP>,9_$FEZI#;0:I_R&+*Z5B;\_@,>N,Y]>#5
MGQ'\,QX@\3:;JU_<VEUHVF '^RKJUW =S@\9'7!XSU]AY& RZ4<+-^\I>]K=
MI_:7?J'UB.FW?9?Y[G@/AS4M$\*^,?"%EI-C<6UAXH'VV\R,C.>....^.]>S
M?&N$S> [^:$_\?-YIO/L6^7C/4@9[X&1GFNA\7_#Z#7[6W_LK^S=-U"U_P"/
M2[^QCCV)R1^OXC J;Q)X,O=>T"#2S?0"X7^SLW97D!& )'!R,\KC.1^-8X#+
MIW:O+5N[O+NUO^(GB%=.^VENEGKW[VU/&8;/Q'XO\)6^AV/AW3=-@M=)TO\
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*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028771301_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028771301_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "& 8H# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !03@$^@S3-X]#^G^-0RRA1^O/^?P 'N37.!6# Y[8ZY_'_ ":_
M+?\ ;;\2B]U/1O XX%W>?;+P>P) QSUP.>AZ^YK]0)KJW"M@MC!X[@8R,8Y!
M[?S]*_$#]I_73JWQBU:].,Z5=K969R#T&#QCOCOD_7@U_'OTO.(UE?AW6P,9
MM.I&<)V=I>]&<7S6:<FKO1W?D?K'@YEOUOB:'UF-U%J46TG[W/'E6SZ*^WGY
M'SA]C\Z6X'_3Y]BQ].W]/\>"">">\_U'^C7%K_QY78Z_C_GM[<[%5YO/FB\B
M?_CWR.G^>G''ZBO\+\/C9Y!F<L?@<TES.M*I9-\R?M7.VCOOI\C_ $&Q]2OF
MV3PR:<(JG*,(-N*MR<J@]X_R^9][?LO?M$3L;7X=^,9S_:*M]BLKOU 7G'!R
M/KR.>>H/Z0Z=J4%Y%^_ \^U_X]+O'8_3U[YZU_/19>?#JFGZK8W'V;4-+!O;
M.[Y[^O?OWYK]</V=?BI_PGF@_P"G3?\ $XTO_0KS ],<\<8XXYZ]*_UR^B;X
M^//XY3PUF^:MN*A!1E*ST48I--[;;G\;^,/A=+(,4\?A(K^S)QYI.WVW&[Z:
M:W_K4^O[/_5'Z#^8K0(!&#TJA9P_Z+]!^&/ZCT]>_%:$'?\ '^E?Z+.499DI
M862<)1NW>\6FD[Z:/1W/YB:6%DTEI=[;-7_KO8V**9O'H?T_QHWCT/Z?XUZ1
MN/HIF\>A_3_&GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[C?2GTR3[C?
M2@"*JTW>#I_HG\N,'\O7^E6:KS]OP_K7.!SNJ,(+&:7!)M[,@<=@,D<9X(!]
M?7! K\&?C!J?]L?$OQ1/ZZQ[_AQD8_\ K>E?O+KT,LUK?P@=;0@8)QD@_@>A
M(P>N.*_!+XJ:;_9OQ!\<?\_%KJX^Q_T[GV]!^E?YN_3-Q&,>2SC>3C_;4U9W
M:<.22O;73[T?O_@99\1)Z7OUM?>Z^1PTW^N/U'\Z6B']]^_X^T]OY=_\\?D5
M_C;4C_PM335USS;NK)7E+H]%\S^ZJ]UA8-+5)-->5GTU^2*_G"&ZMY\_Z/:W
MG^F'/7KVP<^N#7TA^SIXP_X1OXH:?F?_ (E^J?A_CW%?.\T)FM+B#M='UX^A
M_7'^-;&@S?V;KWA>>#_EUO/T[9X_SQDGO^[_ $?^(\5D'B%2U:@ZE/E:E[MG
M.&S32^X^2\4<L6>\(3O%<T:;TLKNT'T:OT/Z'],F@O+:&X@/!Y''3/8@^GKC
MU-:'D!@>>X_3!]/PKR_X>:O/>^%](GGAZV0!NN,#/'YXXZ\X^F.X_M$02GSI
MR;? _P"70\D>Y)QS_GGG_H)X S)YOD>68W6\J,'S-+5NG'[7S[Z['^9F:X?Z
MKCJN#LKQJ36COHI36RONEKM;K9G0T5G?:AUP/(QU[=>F<9Q_2J_VN;[689K<
M" CJ;L$]_P"[@G'!Q^-?6/#8OF;UM=N]WM=LY>:/=?>C9I(LX..O./T'\J@S
M,);C&/\ 9QGV_P#K>_-)9_ZH_0?S%='MW:VO\O7T[]P]@M)>GX[=.MS1HHHK
MH&%%,D^XWTKXG^+/[0/Q?\!2:SJ>@_",^(O"WAG2-6O]8U4>)-&!SHC$L1T(
M))RWOZ&L$G)I+JT@/MNBOYI?V?/^#A3X<?'_ /:;TG]FRR^&6I^&_$%YK']B
M?:KJ^;4/^)H/3;X<7:?==I]Z_HXL=0O)!^]59\X^Z%7O[?X=LUM7PTL,KR3U
MML[K57733<#H0""><Y_2EKYC^*7Q ^+_ (8UD1>#OA];ZYX?M;,WUWJTGB+1
M],-Z<D'Y9!N3U/ SP:_#GQ5_P<0>!?!/[1MM^SEXJ^#FMZ=XH&M'1[N[.L'A
MO4#_ (1P@8[$=N1C-*AAI/9IW[^>O7Y_D!_2\OW3[9Q[<=JCKGO">N+XC\-Z
M/K:@ :I9"\ &  .F,=L\?2M^*0&0K^ _3IZ^_ITZUS5DXXA1N]-':]G;3[@+
M5%%%=8!1110 4444 %%%% !17+:GJ][%YYL8 WV3F[) ..G?'\CGM7XS?&?_
M (+F?LC_  -^/EO^SSXQU6Y'B<WFFV-Y=V=JVH:;8;LAB2I!SGH>H/(P>: /
MW"HKA/"'C72/&WA'1O&^AWMM<Z-KVD_VU97?8Z;C<6^@ZDGOU[&NS_>_YW4
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MSM>\/^GVS\1G_(Z'\ZSIO(FM+B"?_GSZ<_\ UNGO_P#6KL/A[9_VE\2_"_\
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MGG7M_<:HUQ;W%N;5;,$>JL&Y.#P<<CC()!SG%=E2 **** "BBL;4L^=!Y/\
MK\G_ +YXQ[YZ?I[T 6)Y;>+KS^9.WJ<=1V!Z9[5S^HRV-V)[8#[3QT' S^F?
M\X/-9YO8 +B>>].F_9/^/P7>/[-^HR0.F>X[>M?#'Q^_X*-?LH?LZV%S!XJ^
M(&B:WJ%KT\/:3>'^U/7Z?_6_7BS7 +,<%4P*AS^UA.GR_$FYQE!75FOM:^HX
MU<+@9+&XN3C.-I+5III\R^TGNN_J>:?M,_ -M/N;GQQX>M\7(/\ IEH!P1R
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M7Q2_Q2_-G0?YJ'_!;WX;S_#']M?P_P"%=5US4O&^H75GX7_XFMU>_P#'@/\
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M5B\3C%)8F5XZI6E?37HGV*\T,'F^?Y'Z\=L_ET_EP*L3PP>5]GN(/M%O<_\
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MR_%8)<UHVM%)[)Z:7Z??<_H?PEX2Q7$6,C'%^\N:/N[Z.2TM9[W_ !9_)_\
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M!;5=<  W$#YB  HSD@<9KU'_ (+M?LEP_M.?L;ZSXCTNR!\<?"^T_P"$GL0
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MN?7\_P#]7MH:=,=-NK><9^T6OZ>P.,^GZT>=_I?^U_GVQTJ#SH+R:W\CM_\
M6Q]!W/XC(SFO\=^$:_$%7Q#PV#RI/)^7%8>,[7BYQCB*/-MROWE&6^US^_\
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MASC@>PR#QFO5PV987%W2DNUKWU3>UGIJ]4]-A?5M_=_!:_A^9Y=\)O@OX/\
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MQQ[]Z^6S#,Y2UC>]]-_Q_)KY,^ORW+?JMM.VEK^?7\^A!.!_H\, _P!'NO\
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MIW:O+5N[O+NUO^(GB%=.^VENEGKW[VU/&8;/Q'XO\)6^AV/AW3=-@M=)TO\
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0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
